RE: Moderna4 Apr 2022 18:47
From the interims Sep 21.
Moderna: In 2019 Moderna exercised a commercial option to an Affimer® programme and took a number of lead Affimer molecules against that particular target in-house for development. Avacta is not actively involved with this ongoing internal development work at Moderna. The next key milestone would occur if Moderna submits an IND package to the FDA.